<DOC>
	<DOCNO>NCT01487330</DOCNO>
	<brief_summary>The purpose first-in-human study assess technical feasibility , deployment characteristic , safety 23mm SJM Transfemoral Transcatheter Heart Valve delivery system subject severe symptomatic aortic stenosis ( AS ) . This single center , prospective , non-randomized , first-in-human investigational study without concurrent match control .</brief_summary>
	<brief_title>First Human Experience St. Jude Medical TAVI Valve Delivery System</brief_title>
	<detailed_description>Data collect baseline , procedure , discharge ( date hospital discharge 7 day post-implant , whichever occur first ) , 30 day post implant , 3 month post implant , 6 month post implant , 12 month post implant .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Written Informed Consent participation prior procedure . 2 . Legal age host country . 3 . Aortic annulus 1921mm diameter 4 . Senile degenerative aortic stenosis derive mean gradient &gt; 40mmHg jet velocity great 4.0 m/s initial valve area &lt; 1.0 cm2 ( aortic valve area index ≤ 0.6 cm2/m2 ) 5 . NYHA Functional Classification II great . 6 . Predicted operative mortality serious , irreversible morbidity risk &lt; 50 % 30 day . 7 . Suitable peripheral vessel aorta allow access 18 French delivery system . 1 . History cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month ( ≤180 day ) index procedure . 2 . Carotid artery disease require intervention . 3 . Myocardial infarction ( MI ) within 6 month ( ≤180 day ) index procedure . 4 . Native aortic valve congenitally unicuspid , bicuspid , quadricuspid noncalcified see echocardiography . 5 . Mitral tricuspid valvular regurgitation ( grade II ) moderate severe mitral stenosis . 6 . Aortic root angulation &gt; 70 degree ( horizontal aorta ) . 7 . Preexisting prosthetic valve prosthetic ring position . LVEF &lt; 20 % . 8 . Untreated coronary artery disease ( CAD ) require revascularization . 9 . Severe basal septal hypertrophy . 10 . Percutaneous interventional invasive cardiac peripheral procedure ≤ 14 day history previous endocarditis . 11 . Uncontrolled atrial fibrillation ( AF ) chronic AF without long term oral anticoagulation . 12 . Evidence intracardiac mass , thrombus , vegetation . 13 . Hemodynamic instability 14 . Significant pulmonary disease . 15 . Nonreactive pulmonary hypertension . 16 . Chronic steroid use . 17 . Hypersensitivity contraindication anticoagulant antiplatelet medication . 18 . Renal insufficiency evidence serum creatinine &gt; 3.0 endstage renal disease require chronic dialysis . 19 . Morbid obesity define BMI ≥ 35 . 20 . Subject 's iliac artery severe calcification , tortuosity , diameter &lt; 6mm , subject aortofemoral bypass . 21 . Ongoing infection sepsis . 22 . Blood dyscrasia 23 . Significant aortic disease . 24 . Preexisting endovascular stent graft supra infrarenal aorta preexist stent graft ileofemoral artery . 25 . Active peptic ulcer gastrointestinal ( GI ) bleed within past 3 month ( ≤ 90 day ) prior index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>aortic stenosis</keyword>
	<keyword>aortic valve stenosis</keyword>
	<keyword>valvular heart disease</keyword>
	<keyword>aortic valve replacement</keyword>
	<keyword>transcatheter aortic valve implantation</keyword>
	<keyword>TAVI</keyword>
	<keyword>TAVR</keyword>
</DOC>